JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267128

Human PARP9 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PARP9 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4.

View Alternative Names

ADP-ribosyltransferase diphtheria toxin-like 9, ARTD9, AW214463, B aggressive lymphoma protein, BAL, BAL1, BC003281, Bagl, DKFZp666B0810, DKFZp686M15238, EC 2.4.2.30, FLJ26637, FLJ35310, FLJ41418, FLJ43593, MGC156739, MGC7868, MGC:7868, OTTMUSP00000028034, PARP9_HUMAN, Poly (ADP ribose) polymerase family member 9, Poly [ADP-ribose] polymerase 9, RGD1307534

1 Images
Sanger Sequencing - Human PARP9 knockout A549 cell line (AB267128)
  • Sanger seq

Unknown

Sanger Sequencing - Human PARP9 knockout A549 cell line (AB267128)

Homozygous : 1 bp insertion in exon4

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4

Disease

Carcinoma

Product details

Recommended control: Human wild-type A549 cell line (ab255450). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267128-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267128 Human PARP9 knockout A549 cell line", "number":"AB267128-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267128-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267128 Human PARP9 knockout A549 cell line", "number":"AB267128-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PARP9
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PARP9 also known as ADP-ribosyltransferase diphtheria toxin-like 9 is a protein involved in cellular DNA repair and immune response. The protein has a molecular mass of approximately 88 kDa. It is notably expressed in various tissues including lymphoid tissues and immune cells suggesting a role in the immune system. PARP9 possesses domains that may facilitate interactions with other proteins playing a part in regulating cellular repair processes.
Biological function summary

PARP9 enhances DNA repair mechanisms and modulates the immune response. It may work as part of larger protein complexes coordinating with other proteins to maintain genomic stability and regulate transcription. Its involvement in these complexes indicates a supportive role in cellular defense ensuring the integrity of genetic information and proper immune function. Moreover PARP9 may influence signal transduction pathways related to inflammation and cell survival.

Pathways

PARP9 participates in critical networks that govern DNA damage response and immune signaling. It aligns with the NF-kB pathway which controls transcription of DNA cytokine production and cell survival. Additionally PARP9 associates with the innate immune response pathway influencing processes driven by related proteins like STAT1 enhancing the cellular response to external stressors. These interactions reflect its contribution to cellular adaptation and resilience.

PARP9 links to conditions with underlying inflammatory or immune-related components. Its dysregulation associates with autoimmune diseases where it may influence abnormal immune activity. Additionally PARP9 has connections to certain cancers potentially through interactions with proteins like STAT3 which influences cell proliferation and survival. Understanding PARP9's role in these conditions could guide therapeutic strategies targeting abnormal protein interactions and signaling.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com